Waverley Pharma Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was CAD 0.096086 million compared to CAD 0.341927 million a year ago. Net loss was CAD 0.309961 million compared to CAD 0.121712 million a year ago. Basic loss per share from continuing operations was CAD 0.01. Diluted loss per share from continuing operations was CAD 0.01.
For the nine months, sales was CAD 0.363365 million compared to CAD 1.07 million a year ago. Net loss was CAD 0.890476 million compared to CAD 0.456744 million a year ago. Basic loss per share from continuing operations was CAD 0.02 compared to CAD 0.01 a year ago.